SCHEMBL1129299

SCHEMBL1129299

Brc1ccc2cc(Oc3ccccn3)ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.55
CYP2A6 P11509 1/20 0.47
TLR4 O00206 1/20 0.45
TLR2 O60603 1/20 0.45
SCN7A Q01118 6/20 0.44
KCNH2 Q12809 6/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 2/20 0.44
USP2 O75604 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.42
SCN5A Q14524 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN8A Q9UQD0 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
PTGS2 P35354 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL568653 0.84 LTA4H (0.50) TLR4TLR2KDM4ECYP1A2HRH3
SCHEMBL6682445 0.83 EGFR (0.53) TLR4TLR2HTTKDM4ERAB9A
SCHEMBL21388233 0.80 NPC1 (0.57) THRBTLR4TLR2USP2NPSR1
SCHEMBL5686998 0.80 SCN7A (0.47) TLR4TLR2SCN7AKCNH2KDM4E
SCHEMBL2580870 0.80 EGFR (0.50) TLR4TLR2HTTKDM4EHSD17B10
SCHEMBL11143982 0.78 PTGS2 (0.57) TLR4TLR2KDM4EMAPK1CYP1A2
SCHEMBL12419258 0.76 CA1 (0.51) TLR4TLR2SCN7AKCNH2KDM4E
SCHEMBL12129555 0.76 TLR4 (0.56) TLR4TLR2HTTKDM4EHSD17B10
SCHEMBL29612417 0.76 TLR4 (0.56) TLR4TLR2HTTKDM4EHSD17B10
SCHEMBL22061563 0.76 KDM4E (0.48) TLR4TLR2KDM4ECYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
EP-2282742-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 THRB 3107/4885CYP2A6 94/4885TLR4 2326/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 THRB 3107/4885CYP2A6 94/4885TLR4 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.